Oragenics (OGEN) Gains from Sales and Divestitures (2022 - 2023)
Oragenics' Gains from Sales and Divestitures was -$52,399 in Q4 2023.
Powered by 
Analysis
Oragenics (OGEN) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends
For FY2023, Gains from Sales and Divestitures at Oragenics came in at -$29,956.
- In earlier years, Gains from Sales and Divestitures was $10,964 in FY2022.
- The Q4 2023 figure marks the highest quarterly Gains from Sales and Divestitures since Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Oragenics | 2.21 Mn | 2.21 Mn | - |
API Access
Oragenics Gains from Sales and Divestitures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OGEN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gains-from-sales-and-divestitures", "ticker": "OGEN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OGEN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();